What happened Shares of Zomedica (NYSEMKT: ZOM) rose on Monday after the veterinary health company signed a new distribution agreement for its Truforma diagnostic platform. As of 1:25 p.m. EST, Zomedica's stock price was up nearly 7% after rising as much as 14% earlier in the day. So what Zomedica struck a deal with Miller Veterinary Supply. The wholesale veterinary distributor will work with Zomedica's salesforce to drive sales of Truforma in the eastern region of the U.S. Miller will also provide customer service support for the point-of-care diagnostics system for cats and dogs. Zomedica is preparing for the upcoming commercial launch of its Truforma veterinary diagnostics system. Image source: Getty Images. "We could not be happier about signing this distribution agreement with such a reputable and highly experienced organization," Zomedica CEO Robert Cohen said in a press release. "We believe that the principals of Miller share the same commitment to quality, customer service, and value that we hope to be hallmarks of the Truforma line of products." Now what Zomedica will begin selling its Truforma systems on March 30. The patented diagnostic platform is expected to produce precise and reliable results when used to detect diseases in dogs and cats. Zomedica thus expects Truforma to enjoy strong demand in the veterinary marketplace. "It isn't often that an industry-changing product like Truforma comes along," Miller Chief Operating Officer Clay Cass said. "We are honored and excited to have been chosen to help bring this technology to market." 10 stocks we like better than Zomedica Pharmaceuticals Corp.When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Zomedica Pharmaceuticals Corp. wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of November 20, 2020 Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.Source